CD274 and cancer: ATM-ATR inhibitors have demonstrated promising results in pre-clinical models with high toxicities toward cancer cells.107 Some of these inhibitors are being tested in clinical trials but not in combination with PD-L1/PD-1 blockers.108,109 Indeed, no objective reasons for combining them in human clinical trials have existed until now.